CVS Health Corp (CVS · NYSE)

CVS Health shares closed at $86.46, up 1.5% on the day but down 11.0% over the past month and 15.4% over three months, leaving the stock 21.3% below its 52-week high with an RSI of 27. The company has beaten earnings estimates in each of its last four quarters, most recently reporting Q2 EPS of $2.58 versus $1.87 expected, with quarterly revenue of $106.10B and net income of $3.00B, up from a $3.98B net loss in the September 2025 quarter. Trailing revenue sits at $412.64B, up 7.1% year over year, while earnings grew 188.8%, and the stock trades at a P/E of 22.81 against an analyst target of $116.28. Leverage remains notable at $76.31B in total debt (4.6x EBITDA) with a current ratio of 0.87, though the quarter generated $5.65B in free cash flow, and McKesson's extension of its pharmacy supply agreement through June 2032 added a recent positive.